Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31046065.
- Also identified by DOI 10.1001/jamaoncol.2019.0869 and PMC identifier 6499126.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with <i>TP53</i> wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.
Medical subject headings
- Androstenes
- Antineoplastic Agents
- Phenylthiohydantoin
- Prostatic Neoplasms, Castration-Resistant
- Receptors, Androgen